DOI: http://dx.doi.org/10.18203/2349-3933.ijam20174295

Evaluation of iron status in patients with end stage renal disease

Anith Kumar Mambatta, Murali Alagesan, Mohammed Meeran, Joshua L. Rein, Sivaramakrishnan Ganesan, Anil C. Mathew, Venu Gurusamy, Jayachandran Kuppusamy, Madhav C. Menon

Abstract


Background: Anaemia is almost universal in haemodialysis patients. Here, we evaluated the utility and clinical implications of the commonly employed tests in assessing iron status in haemodialysis patients.

Methods: In this prospective observational study, we enrolled 100 prevalent haemodialysis patients, and measured transferrin saturation (TSAT) and serum ferritin at enrolment. Patients were categorized to have normal, deficient, overload, or indeterminate status of iron based on KDOQI guidelines. To study anaemia trend, haemoglobin (Hb) level at time of enrolment, as well as levels 3-months before and 3-months after enrolment, were collected. Patient survival outcomes were also obtained till October 2016.

Results: Using serum ferritin and TSAT, iron status was determinable in 48% of the patients ie 20%-normal iron status, 25% - iron deficiency, 3% - iron overload. Fifty-two percent of the patients’ iron status was indeterminate by current parameters. In spite of being on standard-of-care treatment in our centre, we observed that mean-Hb level of patients in the indeterminate group showed insignificant increases compared to normal- and deficient-groups. Mean delta-Hb levels over 6-months were 0.80±1.54 g/dl in the indeterminate group, compared to 1.87±1.95 g/dl in the deficient group (P=0.03). In our cohort, 57% had died and 5 lost follow-ups during the study (P=0.30 between groups).

Conclusions: Serum ferritin and TSAT accurately categorized the iron status of 48% haemodialysis patients in our study. Divergent serum ferritin and TSAT values, or an iron indeterminate state was prevalent in 52% of our urban dialysis cohort. The indeterminate group had inferior increases in Hb over time with current treatment, showing clinical relevance of this finding. Our data suggests the need for more sensitive indices to accurately assess iron status, and improve anaemia management.


Keywords


ESRD patients, Iron status, Serum ferritin, TSAT

Full Text:

PDF

References


KDOQI. Clinical Practice Guidance and Clinical Practice Recommendations for anaemia in Chronic Kidney Disease: 2007 Update of Haemoglobin target. Am J Kidney Dis. 2007;50:471-530.

Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P. Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis. Clin J Am Soc Nephrol. 2009;4:755-62.

Sonnweber T, Theurl I, Seifert M, Schroll A, Eder S, Mayer G, et al. Impact of Iron treatment on immune effector function and cellular iron status of circulating monocytes in dialysis patients. Nephrol Dial Transplant. 2011;26:977-87.

Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, et al. Iron administration and clinical outcomes in haemodialysis patients. J Am Soc Nephrol. 2002;13:734-44.

Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36:282-93.

MacDougall IC, Hutton RD, Cavill I, Coles GA, Williams JD. Poor response to treatment of renal anaemia with erythropoietin corrected by iron given intravenously. BMJ. 1989;299:157-8.

Sakiewicz P, Paganini E. The use of iron in patients on dialysis- mistakes and misconceptions. J Nephrol. 1998;11:5-15.

Horl WH. Clinical aspects of iron use in the anaemia of kidney disease. J Am Soc Nephrol. 2007;18:382-93.

René É, Lazrak HH, Laurin LP, Elftouh N, Vallée M, Lafrance JP. Association of erythropoiesis stimulating agents and the incidence risk of cancer diagnosis among chronic dialysis patients: a nested case-control study. Nephrol Dial Transplant. 2017;32:1047-52.

Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial. 2004;17:57-60.

Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Kuhn L, et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014;311:1317-26.

Wish JB. Assessing iron status: beyond serum ferritin and transferrin saturation. Clin J Am Soc Nephrol. 2006;1:S4-8.

Nissenson AR. Hyporesponsiveness to erythropoietin: overview, 1996. Perit Dial Int. 1996;16:417-20.

Eschabach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, et al. Recombinant human erythropoietin in anaemic patients with end stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000.

Aggarwal HK, Nand N, Singh S, Singh M, Hemant, Kaushik G. Comparison of oral versus intravenous iron therapy in predialysis patients of chronic renal failure receiving recombinant human erythropoietin. J Assoc Physicians India. 2003;51:170-4.

Gupta M, Kannan M, Gupta S, Saxena R. Contribution of iron deficiency to anemia in chronic renal failure. Indian J Pathol Microbiol. 2003;46:563-4.

Fernandez-Rodriguez AM, Guindeo-Casasus MC, Molero-Labarta T, Domínguez-Cabrera C, Hortal-Casc n L, Pérez-Borges P, et al. Diagnosis of iron deficiency in chronic renal failure. Am J Kidney Dis. 1999;34:508-13.

Coyne DW. Hepcidin: clinical utility as a diagnostic tool and therapeutic target. Kidney Int. 2011;80:240-4.

Rafi A, Karkar A, Abdelrahman M. Monitoring iron status in end stage renal disease patients on haemodialysis. Saudi J Kidney Dis Transplant. 2007;18:73-8.

Caville I. Disorders of iron metabolism. Diagnostic methods. Clin Haematol. 1982;11:259-73.

Cook JD, Skikne BS, Baynes RD. Serum transferrin receptor. Annu Rev Med. 1993;44:63-74.

Cooper MJ, Zlotkin SH. Day-to-day variation of transferrin receptor and ferritin in healthy men and women. Am J Clin Nutr. 1996;64:738-42.

Macdougall IC. Monitoring of iron status and iron supplementation in patients treated with erythropoietin. Curr Opin Nephrol Hypertens. 1994;3:620-5.

Neff M. Algorithm for the treatment of anaemia in ESRD. Network Forum Quality Assurance Committee; 1995.

Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in haemodialysis patients. J Am Soc Nephrol. 1996;7:2654-7.

Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996;50:1694-9.

Silverberg DS, Laina A, Peer G, Kaplan E, Levi BA, Frank N, et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996;27:234-8.

Silverberg DS, Blum M, Peer G, Kaplan F, Laina A. Intravenous ferric saccharate as an iron supplement in dialysis patients. Nephron. 1996;72:413-7.

Fishbane S, Galgano C, Langley RC Jr, Cranfield W, Maesaka JK. Reticulocyte haemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-22.

Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, et al. Reticulocyte haemoglobin content predicts functional iron deficiency in hemodialysis patients receiving EPO. Am J Kidney Dis. 1997;30:912-3.

Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37:93-130.

Cullen P, Söffker J, Höpfl M, Bremer C, Schlaghecken R, Mehrens T, et al. Hypochromic red cells and reticulocyte haemoglobin content as markers of iron‐deficient erythropoiesis in patients undergoing chronic haemodialysis. Nephrol Dial Transplant. 1999;14:659-65.

Fishbane S, Galgano C, Langley RC Jr, Canfield W, Maesaka JK. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-22.

Mittman N, Sreedhara R, Mushnick R, Chattopadhyay J, Zelmanovic D, Vaseghi M, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving EPO. Am J Kidney Dis. 1997;30:912-22.

KDOQI; National Kidney Foundation. Clinical Practice Guidelines and Clinical Practice Recommendations for Anaemia in Chronic Kidney Disease. Am J Kidney Dis. 2006;47:S11-145.

European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 1999;14:S14-15.

Braun J, Lindner K, Schreiber M, Heidler A, Hörl WH. Percentage of hypochromic red cells as predictor of erythropoietic and iron response after i.v. iron supplementation in maintenance haemodialysis patients. Nephrol Dial Transplant. 1997;12:1173-81.

Jones CH, Richardson D, Ayers S, Newstead CG, Will EJ, Davison AM. Percentage hypochromic red cells and the response to intravenous iron therapy in anaemic haemodialysis patients. Nephrol Dial Transplant. 1998;13:2873-6.

Tessitore N, Solero P, Gammaro, Sabato A, Maschio G. Iron status and low dose intravenous Fe gluconate in hemodialysis patients on maintenance erythropoietin (Abstract). J Am Soc Nephrol. 1998;9:272.

Tessitore N, Solero GP, Lippi G, Bassi A, Faccini GB, Bedogna V, et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant. 2001;16:1416-23.